New cocktail of four drugs aims to tackle childhood cancers that Won't go away
NCT ID NCT05468359
First seen Jun 24, 2026 · Last updated Jun 27, 2026 · Updated 1 time
Summary
This study is testing a combination of four drugs—atezolizumab, sorafenib, bevacizumab, and cyclophosphamide—in children and young adults with solid tumors that have come back or not responded to standard treatment. The goal is to find safe doses and see if the combination can shrink tumors. The trial has two parts: the first focuses on safety and dosing, and the second looks at how well the treatment works in specific rare cancers like fibrolamellar carcinoma and hepatocellular carcinoma.
What this could mean
Our plain-language read of the trial. This is informational only — not medical advice or a prediction.
Active substance
Atezolizumab, sorafenib, bevacizumab, and cyclophosphamide
What this could lead to
If successful, this could offer a new treatment option for children with relapsed or hard-to-treat solid tumors, including rare liver cancers.
What could go wrong
This is an early-phase trial with a small number of participants. The drug combination may cause serious side effects, and it is not yet known if it will shrink tumors or improve survival.
Disclaimer
Read more
Show less
This is a summary of
the original study
.
Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for HEPATOCELLULAR CARCINOMA are added.
By submitting, you agree to our Terms of use
Conditions
The condition(s) this trial relates to.
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Study contacts
-
Contact
Phone: •••-•••-•••• Email: •••••@•••••
Locations
-
Methodist Le Bonheur Healthcare
WITHDRAWNGermantown, Tennessee, 38138, United States
-
St. Jude Children's Research Hospital
RECRUITINGMemphis, Tennessee, 38105, United States
Contact Phone: •••-•••-•••• Email: •••••@•••••
Contact